SCHEMBL2473980

SCHEMBL2473980

Cc1ccc(NC(=O)N(CCCN2CCOCC2)Cc2ccc(C(=O)Nc3ccccc3N)cc2)cc1F

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
MAPT P10636 3/20 0.51
HSD17B10 Q99714 3/20 0.51
TSHR P16473 3/20 0.49
OPRM1 P35372 1/20 0.49
OPRD1 P41143 1/20 0.49
HDAC1 Q13547 3/20 0.47
KDM4E B2RXH2 5/20 0.47
GAA P10253 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NAMPT P43490 1/20 0.46
LMNA P02545 2/20 0.46
HPGD P15428 2/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TP53 P04637 1/20 0.46
THRB P10828 1/20 0.46
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473792 0.94 ALDH1A1 (0.54) ALDH1A1MAPTHSD17B10TSHROPRM1
SCHEMBL2476586 0.93 HSD17B10 (0.55) ALDH1A1MAPTHSD17B10TSHROPRM1
SCHEMBL2477106 0.90 OPRM1 (0.54) ALDH1A1MAPTHSD17B10TSHROPRM1
SCHEMBL2477227 0.90 OPRM1 (0.52) ALDH1A1MAPTHSD17B10TSHROPRM1
SCHEMBL4219720 0.90 ALDH1A1 (0.51) ALDH1A1MAPTHSD17B10TSHROPRM1
SCHEMBL2474354 0.89 MAPT (0.57) ALDH1A1MAPTHSD17B10TSHROPRM1
SCHEMBL2478140 0.89 HSD17B10 (0.52) ALDH1A1MAPTHSD17B10TSHROPRM1
SCHEMBL2475895 0.89 MCHR1 (0.55) ALDH1A1MAPTHSD17B10TSHROPRM1
SCHEMBL3835327 0.89 ALDH1A1 (0.50) ALDH1A1MAPTHSD17B10TSHROPRM1
SCHEMBL2474808 0.88 ALDH1A1 (0.54) ALDH1A1MAPTHSD17B10TSHRHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 ALDH1A1 1040/4885MAPT 1576/4885HSD17B10 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.